MA41985A - Composition pour le nettoyage du côlon et le traitement de troubles gastro-intestinaux - Google Patents

Composition pour le nettoyage du côlon et le traitement de troubles gastro-intestinaux

Info

Publication number
MA41985A
MA41985A MA041985A MA41985A MA41985A MA 41985 A MA41985 A MA 41985A MA 041985 A MA041985 A MA 041985A MA 41985 A MA41985 A MA 41985A MA 41985 A MA41985 A MA 41985A
Authority
MA
Morocco
Prior art keywords
treatment
composition
gastrointestinal disorders
colon cleansing
cleansing
Prior art date
Application number
MA041985A
Other languages
English (en)
Other versions
MA41985B1 (fr
Inventor
Mark G Currie
Christopher Leitheiser
Robert Solinga
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Publication of MA41985A publication Critical patent/MA41985A/fr
Publication of MA41985B1 publication Critical patent/MA41985B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA41985A 2015-05-01 2016-04-29 Composition pour le nettoyage du côlon et le traitement de troubles gastro-intestinaux MA41985B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562156077P 2015-05-01 2015-05-01
PCT/US2016/030061 WO2016178979A1 (fr) 2015-05-01 2016-04-29 Composition pour le nettoyage du côlon et le traitement de troubles gastro-intestinaux

Publications (2)

Publication Number Publication Date
MA41985A true MA41985A (fr) 2018-03-07
MA41985B1 MA41985B1 (fr) 2023-04-28

Family

ID=55953439

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41985A MA41985B1 (fr) 2015-05-01 2016-04-29 Composition pour le nettoyage du côlon et le traitement de troubles gastro-intestinaux

Country Status (23)

Country Link
US (2) US10618938B2 (fr)
EP (2) EP4218789A3 (fr)
JP (5) JP6930919B2 (fr)
KR (2) KR102783759B1 (fr)
CN (2) CN108040482B (fr)
CA (2) CA3172777A1 (fr)
CY (1) CY1126031T1 (fr)
DK (1) DK3288578T5 (fr)
EA (1) EA201792401A1 (fr)
ES (1) ES2947591T3 (fr)
FI (1) FI3288578T3 (fr)
HR (1) HRP20230381T1 (fr)
HU (1) HUE061954T2 (fr)
LT (1) LT3288578T (fr)
MA (1) MA41985B1 (fr)
MD (1) MD3288578T2 (fr)
MX (2) MX2017013928A (fr)
PL (1) PL3288578T3 (fr)
PT (1) PT3288578T (fr)
RS (1) RS64160B1 (fr)
SI (1) SI3288578T1 (fr)
SM (1) SMT202300114T1 (fr)
WO (1) WO2016178979A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3288578T2 (ro) * 2015-05-01 2023-08-31 Ironwood Pharmaceuticals Inc Compoziții pentru curățarea colonului și tratamentul tulburărilor gastrointestinale
US11021514B2 (en) 2016-06-01 2021-06-01 Athira Pharma, Inc. Compounds
MX2024006317A (es) * 2021-11-24 2024-06-19 Ironwood Pharmaceuticals Inc Proceso sintetico para la produccion de agonistas del receptor de guanilato ciclasa c (gcc) modificados.
JP2024541769A (ja) * 2021-11-24 2024-11-12 アイアンウッド ファーマシューティカルズ， インコーポレイテッド 修飾ｇｃｃ受容体アゴニストの産生のための合成プロセス
IL313184A (en) 2021-11-29 2024-07-01 Ironwood Pharmaceuticals Inc Pharmaceutical compositions for the treatment of visceral pain
WO2026050206A1 (fr) * 2024-08-27 2026-03-05 Ironwood Pharmaceuticals, Inc. Combinaisons d'agonistes du récepteur de glp-1 et de guanylate cyclase c (gc-c)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH689139A5 (de) 1995-04-03 1998-10-30 Cerbios Pharma Sa Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung.
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
EP1911763B1 (fr) * 2003-01-28 2010-08-11 Ironwood Pharmaceuticals, Inc. Compositions pour le traitement de troubles gastrointestinaux
US7494979B2 (en) * 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
WO2007022531A2 (fr) * 2005-08-19 2007-02-22 Microbia, Inc. Compositions et methodes de traitement de troubles gastro-intestinaux
US20110172126A1 (en) * 2008-09-03 2011-07-14 Xenome Ltd Libraries of peptide conjugates and methods for making them
UA108636C2 (xx) * 2010-02-17 2015-05-25 Пептид
DK2681236T3 (en) * 2011-03-01 2018-04-16 Synergy Pharmaceuticals Inc PROCEDURE FOR MANUFACTURING GUANYLATE CYCLASE-C-AGONISTS
WO2014131024A2 (fr) 2013-02-25 2014-08-28 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et applications associées
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
WO2016015055A1 (fr) 2014-07-25 2016-01-28 Ironwood Pharmaceuticals, Inc. Compositions de nettoyage du côlon
MD3288578T2 (ro) * 2015-05-01 2023-08-31 Ironwood Pharmaceuticals Inc Compoziții pentru curățarea colonului și tratamentul tulburărilor gastrointestinale

Also Published As

Publication number Publication date
MX2017013928A (es) 2018-01-15
EA201792401A1 (ru) 2018-05-31
PL3288578T3 (pl) 2023-08-14
ES2947591T3 (es) 2023-08-11
LT3288578T (lt) 2023-04-25
CA2984437A1 (fr) 2016-11-10
JP2020203954A (ja) 2020-12-24
MD3288578T2 (ro) 2023-08-31
US10618938B2 (en) 2020-04-14
BR112017023539A2 (pt) 2018-08-14
SI3288578T1 (sl) 2023-07-31
JP2025169325A (ja) 2025-11-12
WO2016178979A1 (fr) 2016-11-10
JP2018519254A (ja) 2018-07-19
JP2022121734A (ja) 2022-08-19
CN108040482A (zh) 2018-05-15
EP3288578A1 (fr) 2018-03-07
MX2022013283A (es) 2022-12-13
EP3288578B1 (fr) 2023-03-15
CN108040482B (zh) 2022-03-29
CA2984437C (fr) 2025-11-18
JP2024015335A (ja) 2024-02-01
KR20250042844A (ko) 2025-03-27
MA41985B1 (fr) 2023-04-28
EP4218789A3 (fr) 2023-09-27
US20180148476A1 (en) 2018-05-31
DK3288578T5 (da) 2024-10-07
HUE061954T2 (hu) 2023-09-28
DK3288578T3 (da) 2023-05-01
FI3288578T3 (fi) 2023-05-03
RS64160B1 (sr) 2023-05-31
CA3172777A1 (fr) 2016-11-10
KR102783759B1 (ko) 2025-03-21
HRP20230381T1 (hr) 2023-07-07
CY1126031T1 (el) 2023-11-15
KR20180005675A (ko) 2018-01-16
US20240199697A1 (en) 2024-06-20
EP3288578B8 (fr) 2023-03-29
SMT202300114T1 (it) 2023-05-12
EP4218789A2 (fr) 2023-08-02
CN114716514A (zh) 2022-07-08
JP6930919B2 (ja) 2021-09-01
PT3288578T (pt) 2023-03-28

Similar Documents

Publication Publication Date Title
EP3481387A4 (fr) Methodes et compositions pour le traitement de troubles épileptiques
EP3448398A4 (fr) Compositions et méthodes pour le traitement de troubles cutanés
EP3340982A4 (fr) Composés pour le traitement de troubles immunitaires et inflammatoires
EP3328376A4 (fr) Méthodes et compositions pour le traitement de troubles de la reprogrammation métabolique
EP3465212A4 (fr) Régulation du microbiote intestinal pour le traitement de troubles neurodégénératifs
EP3347469A4 (fr) Méthodes et compositions pour le traitement du glaucome
EP3500267A4 (fr) Compositions de nicotinamide riboside et de ptérostilbène et méthodes pour le traitement de troubles neurodégénératifs
FR3046933B1 (fr) Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
EP3302379A4 (fr) Compositions et méthodes pour le traitement du ptérygion
EP3180022A4 (fr) Cassette d'expression améliorée pour le conditionnement et l'expression de variantes du facteur viii pour le traitement des troubles de l'hémostase
MA41299A (fr) Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite
EP3368088C0 (fr) Compositions et méthodes pour le traitement de troubles du peroxisome et de leucodystrophies
MA54925A (fr) Compositions pour le traitement de troubles acido-basiques
EP3704108A4 (fr) Composés et compositions pour le traitement de troubles hématologiques
EP3341391A4 (fr) Compositions et procédés pour le traitement de la douleur
MA42953A (fr) Composés et compositions pour le traitement de troubles oculaires
EP3328864A4 (fr) Composés et compositions thérapeutiques pour le traitement de troubles sociaux et de troubles liés à la toxicomanie
MA41985A (fr) Composition pour le nettoyage du côlon et le traitement de troubles gastro-intestinaux
MA39927A (fr) Inhibiteurs de glyt1 pour le traitement de troubles hématologiques
EP3368048A4 (fr) Méthodes et compositions pour le traitement de l'amyloïdose
EP3442554A4 (fr) Compositions et méthodes pour le traitement de troubles associés à la néovascularisation
EP3506927A4 (fr) Compositions de reeline pour le traitement des troubles neurologiques
EP3364965A4 (fr) Méthodes et compositions pour le traitement de maladies neurodégénératives
EP3373922A4 (fr) Compositions et méthodes pour le traitement de l'homocystinurie
EP3344337A4 (fr) Méthodes et compositions pour le traitement de troubles associés à une accumulation du glycogène cytoplasmique